Actelion Company Profile (OTCMKTS:ALIOF)

Analyst Ratings

Consensus Ratings for Actelion (OTCMKTS:ALIOF) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2015HSBCInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Actelion (OTCMKTS:ALIOF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/20/2015$1.61$1.90ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2015$1.28$1.68ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2015$1.13$0.81ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/21/2014$1.50$1.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014$1.37$2.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2014$1.12$1.65ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Actelion (OTCMKTS:ALIOF)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Actelion (OTCMKTS:ALIOF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Actelion (OTCMKTS:ALIOF)
DateHeadline
07/22/16 12:13 PMActelion (ALIOF) Beats Q2 Earnings & Revenues, View Up -
07/21/16 08:00 PMActelion H1 Net Income Rises
07/21/16 08:00 PMActelion H1 Net Income Rises - Quick Facts
07/19/16 10:56 AMETF’s with exposure to Actelion Ltd. : July 19, 2016 -
06/28/16 10:14 AMActelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 -
06/27/16 10:12 AMActelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 27, 2016 -
06/17/16 10:50 AMActelion Ltd. – Value Analysis (US OTC:ALIOF) : June 17, 2016 -
06/15/16 07:09 AMActelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 15, 2016 -
04/22/16 02:01 PMETF’s with exposure to Actelion Ltd. : April 22, 2016 -
04/22/16 08:19 AMActelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2016 By the Numbers -
04/11/16 02:45 PMClovis Hits 52-week Low Post Rociletinib Briefing Documents -
04/08/16 03:40 PMIonis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study -
04/08/16 02:35 PMIntercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote -
04/08/16 12:55 PMIllumina Unveils BaseSpace Suite, Boosts Precision Medicine -
04/06/16 09:10 AMIronwood Slumps, Halts Development of Gastroparesis Drug -
04/05/16 10:20 AMAbbVie Up, Wins CHMP Backing for Humira's Expanded Use -
02/26/16 10:50 AMSarepta's Q4 Loss Wider than Expected, Eteplirsen in Focus -
02/26/16 08:50 AMKeryx Posts Wider-than-Expected Loss in Q4, Auryxia Grows -
02/26/16 08:45 AMIonis Incurs Wider-than-Expected Loss in Q4, Shares Down -
02/26/16 08:35 AMGeron Q4 Loss In-Line with Estimates, Imetelstat in Focus -
02/26/16 07:15 AMAnika Therapeutics (ANIK) Jumps: Stock Moves Up 8% -
02/09/16 12:57 AMActelion Profit Jumps, Proposes Higher Dividend; Sees Growth In FY16 Core Income - (RTTNews.com) - Biopharmaceutical company Actelion Ltd. (ALIOF.PK) Tuesday said that its fourth-quarter net income attributable to shareholders climbed to 99.69 million Swiss francs from last year's 27.79 million francs. Earnings per share were 0.91 franc ...
01/28/16 07:04 AMActelion Ltd. breached its 50 day moving average in a Bullish Manner : January 28, 2016 -
01/01/16 07:17 AMActelion Ltd. breached its 50 day moving average in a Bearish Manner : January 1, 2016 -
12/24/15 08:30 AMThe Zacks Analyst Blog Highlights: Actelion, Amgen, Gilead, AbbVie and BioMarin -
12/23/15 02:55 PMActelion's Uptravi Approved in the U.S. for PAH Treatment -
12/23/15 01:48 PMBiotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved -
12/21/15 07:58 AMActelion Ltd. breached its 50 day moving average in a Bearish Manner : December 21, 2015 -
12/16/15 09:07 AMActelion Ltd. – Value Analysis (US OTC:ALIOF) : December 16, 2015 -
12/14/15 03:40 PMHorizon (HZNP) To Acquire Crealta Holdings in a $510M Deal -
12/09/15 02:35 PMAlexion (ALXN) Gains after Kanuma Receives FDA Approval -
12/03/15 02:35 PMBaxalta Wins CHMP Backing for Sanquin to Start Production -
12/03/15 07:00 AMCytokinetics (CYTK) Looks Good: Stock Moves 8.8% Higher -

Social

About Actelion

Actelion logoActelion Ltd. is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of innovative drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH). The Company's product portfolio include PAH, Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost). PAH is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. Opsumit is an orally available endothelin receptor antagonist (ERA). Tracleer is an orally available endothelin receptor antagonist (ERA). Uptravi is an oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH. Veletri (epoprostenol for injection) is an intravenous prostacyclin. Ventavis is an inhaled formulation of iloprost, a synthetic compound similar to prostacyclin (PGI2).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: ALIOF
  • CUSIP:
Key Metrics:
  • Previous Close: $172.24
  • 50 Day Moving Average: $166.24
  • 200 Day Moving Average: $150.31
  • P/E Ratio: 32.87
  • P/E Growth: 1.73
  • Market Cap: $18.07B
  • Beta: 1.37
  • Current Year EPS Consensus Estimate: $7.22 EPS
  • Next Year EPS Consensus Estimate: $7.17 EPS
Additional Links:
Actelion (OTCMKTS:ALIOF) Chart for Sunday, July, 24, 2016